Ameliorative role of metformin on lipopolysaccharide-mediated liver malfunction through suppression of inflammation and oxidative stress in rats. (2nd January 2022)

• Record Type: Journal Article
• Authors: Beheshti, Farimah; Hosseini, Mahmoud; Arab, Zohreh; Asghari, Amir; Anaeigoudari, Akbar
• Is Part Of: Toxin reviews. Volume 41:Number 1(2022)
• Page Start: 55
• Page End: 63
• Publication Date: 2022-01-02
• Subjects: Lipopolysaccharide -- liver -- inflammation -- oxidative stress; Toxicology -- Periodicals; Toxins -- Periodicals; 615.905
• DOI: 10.1080/15569543.2020.1833037
• Languages: English
• ISSNs: 1556-9543

Abstract

Abstract: Liver is susceptible to oxidative stress and inflammation. The effect of metformin on lipopolysaccharide (LPS)-mediated liver malfunction was investigated. Rats were grouped into (1) control, (2) LPS, (3–5) LPS as well as 50, 100, and 150 mg/kg of metformin for 5 weeks. LPS increased liver enzymes, IL-6, and malondialdehyde (MDA) ( p < 0.05 and p < 0.001) whereas metformin reduced them ( p < 0.05 to p < 0.001). LPS decreased total protein, albumin, total thiol, SOD and CAT ( p < 0.05 and p < 0.001), and metformin attenuated the effect of LPS ( p < 0.05 to p < 0.001). The protective effect of metformin is probably mediated via suppression of inflammation and improvement of oxidative stress status.